explore -WSS

explore

author：hotspot 2025-10-02 06:40:20 - browse：66

Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to say someone overpaid?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how biotech’s downturn has made life difficult not just for startups but also the VCs they rely on for much-needed funding. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

For more on what we cover, here’s more on Gilead; here’s the news on Inhibrx; here’s the latest on biotech venture capital; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： AI models in health care face new federal disclosure requirements

WSS

STAT Summit: Biotech founders on deal

The woman behind the Dana Farber

Chemotherapy shortages won’t get better under Biden’s latest plan

The explosion of genetic testing requires a new approach

Beam Therapeutics to lay off 20% of its staff, re

Teach medical students about patients with intellectual disabilities

Wikipedia

explore

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Readout Newsletter: Today's biggest biotech updates

23andMe had bad news about my health. I wish a person had delivered it

Why health workers in Gaza are injured or die at high rates

Wildfire smoke exposes gaps in outdoor worker protections

FDA needs staff influx to meet gene therapy needs, Marks says

Tori Bowie and the unacceptable rates of Black maternal death

First Opinion Podcast: Long Covid needs a new approach

Virginia high school admissions case could be legal follow

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

STAT Summit: Biotech founders on deal

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Medicare reduced heart disease by changing how it pays doctors

The woman behind the Dana Farber

Spinal cord stimulation reduces pain in amputees, study finds

In diabetes hearing, Sanders takes on a new foe: food makers

focus

Wikipedia

focus

focus